Discriminating between Waldenström macroglobulinemia and marginal zone lymphoma using logistic LASSO regression

References

• Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the world health organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–2390.
   PubMed Web of Science ®Google Scholar
• Campo E, Swerdlow SH, Harris NL, et al. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood. 2011;117(19):5019–5032.
   PubMed Web of Science ®Google Scholar
• Vos JM, Minnema MC, Wijermans PW, et al. Guideline for diagnosis and treatment of waldenström’s macroglobulinaemia. Neth J Med. 2013;71(2):54–62.
   PubMed Web of Science ®Google Scholar
• Molina TJ, Lin P, Swerdlow SH, et al. Marginal zone lymphomas with plasmacytic differentiation and related disorders. Am J Clin Pathol. 2011;136(2):211–225.
   PubMed Web of Science ®Google Scholar
• Cao X, Medeiros LJ, Xia Y, et al. Clinicopathologic features and outcomes of lymphoplasmacytic lymphoma patients with monoclonal IgG or IgA paraprotein expression. Leuk Lymphoma. 2016;57(5):1104–1113.
   PubMed Web of Science ®Google Scholar
• Owen RG. Developing diagnostic criteria in waldenstrom’s macroglobulinemia. Semin Oncol. 2003;30(2):196–200.
   PubMed Web of Science ®Google Scholar
• García-Sanz R, Jiménez C, Puig N, et al. Origin of Waldenstrom’s macroglobulinaemia. Best Pract Res Clin Haematol. 2016;29(2):136–147.
   PubMed Web of Science ®Google Scholar
• Sebestyén A, Berczi L, Mihalik R, et al. Syndecan-1 (CD138) expression in human non-Hodgkin lymphomas. Br J Haematol. 1999;104(2):412–419.
   PubMed Web of Science ®Google Scholar
• Berger F, Felman P, Thieblemont C, et al. Non-MALT marginal zone B-cell lymphomas: a description of clinical presentation and outcome in 124 patients. Blood. 2000;95(6):1950–1956.
   PubMed Web of Science ®Google Scholar
• Berger F, Traverse-Glehen A, Felman P, et al. Clinicopathologic features of Waldenstrom’s macroglobulinemia and marginal zone lymphoma: are they distinct or the same entity? Clin Lymphoma. 2005;5(4):220–224.
   PubMedGoogle Scholar
• Treon SP, Xu L, Yang G, et al. MYD88 L265P somatic mutation in Waldenström’s macroglobulinemia. N Engl J Med. 2012;367(9):826–833.
   PubMed Web of Science ®Google Scholar
• Martinez-Lopez A, Curiel-Olmo S, Mollejo M, et al. MYD88 (L265P) somatic mutation in marginal zone B-cell lymphoma. Am J Surg Pathol. 2015;39(5):644–651.
   PubMed Web of Science ®Google Scholar
• Jiménez C, Sebastián E, Chillón MC, et al. MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenström’s macroglobulinemia. Leukemia. 2013;27(8):1722–1728.
   PubMed Web of Science ®Google Scholar
• Shin SY, Lee ST, Kim HY, et al. Detection of MYD88 L265P in patients with lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia and other B-cell non-Hodgkin lymphomas. Blood Res. 2016;51(3):181–186.
   PubMed Web of Science ®Google Scholar
• Treon SP, Cao Y, Xu L, et al. Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia. Blood. 2014;123(18):2791–2796.
   PubMed Web of Science ®Google Scholar
• Cao XX, Meng Q, Cai H, et al. Detection of MYD88 L265P and WHIM-like CXCR4 mutation in patients with IgM monoclonal gammopathy related disease. Ann Hematol. 2017;96(6):971–976.
   PubMed Web of Science ®Google Scholar
• van Dongen JJ, Lhermitte L, Böttcher S, et al. EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia. 2012;26(9):1908–1975.
   PubMed Web of Science ®Google Scholar
• Heinze G, Schemper M. A solution to the problem of separation in logistic regression. Stat Med. 2002;21(16):2409–2419.
   PubMed Web of Science ®Google Scholar
• Smith GCS, Seaman SR, Wood AM, et al. Correcting for optimistic prediction in small data sets. Am J Epidemiol. 2014;180(3):318–324.
   PubMed Web of Science ®Google Scholar
• Musoro JZ, Zwinderman AH, Puhan MA, et al. Validation of prediction models based on lasso regression with multiply imputed data. BMC Med Res Methodol. 2014;14:116.
   PubMed Web of Science ®Google Scholar
• van Buuren S. Flexible imputation of missing data. 2nd ed. Boca Raton (FL): CRC Press; 2018.
   Google Scholar
• Friedman JH, Hastie T, Tibshirani R. Regularization paths for generalized linear models via coordinate descent. J Stat Softw. 2010;33(1):1–22.
   PubMed Web of Science ®Google Scholar
• Hoogland J, Barreveld M, Debray TPA, et al. Handling missing predictor values when validating and applying a prediction model to new patients. Stat Med. 2020;39(25):3591–3607.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Kyle RA, Anagnostopoulos A, et al. Diagnosis and management of Waldenstrom’s macroglobulinemia. J Clin Oncol. 2005;23(7):1564–1577.
   PubMed Web of Science ®Google Scholar
• Stübgen JP. Autoantibody-mediated sensory polyneuropathy associated with indolent B-cell non-Hodgkin’s lymphoma: a report of two cases. J Clin Neurol. 2015;11(3):283–286.
   PubMed Web of Science ®Google Scholar
• Pangalis GA, Kyrtsonis MC, Kontopidou FN, et al. Differential diagnosis of Waldenstrom’s macroglobulinemia and other B-cell disorders. Clin Lymphoma. 2005;5(4):235–240.
   PubMedGoogle Scholar
• Ghobrial IM, Gertz MA, Fonseca R. Waldenström macroglobulinaemia. Lancet Oncol. 2003;4(11):679–685.
   PubMed Web of Science ®Google Scholar
• Arcaini L, Varettoni M, Boveri E, et al. Distinctive clinical and histological features of Waldenström’s macroglobulinemia and splenic marginal zone lymphoma. Clin Lymphoma Myeloma Leuk. 2011;11(1):103–105.
   PubMed Web of Science ®Google Scholar
• Bassarova A, Trøen G, Spetalen S, et al. Lymphoplasmacytic lymphoma and marginal zone lymphoma in the bone marrow: paratrabecular involvement as an important distinguishing feature. Am J Clin Pathol. 2015;143(6):797–806.
   PubMed Web of Science ®Google Scholar
• Lin P, Molina TJ, Cook JR, et al. Lymphoplasmacytic lymphoma and other non-marginal zone lymphomas with plasmacytic differentiation. Am J Clin Pathol. 2011;136(2):195–210.
   PubMed Web of Science ®Google Scholar
• Sovani V, Harvey C, Haynes AP, et al. Bone marrow trephine biopsy involvement by lymphoma: review of histopathological features in 511 specimens and correlation with diagnostic biopsy, aspirate and peripheral blood findings. J Clin Pathol. 2014;67(5):389–395.
   PubMed Web of Science ®Google Scholar
• Arber DA, George TI. Bone marrow biopsy involvement by non-Hodgkin’s lymphoma: frequency of lymphoma types, patterns, blood involvement, and discordance with other sites in 450 specimens. Am J Surg Pathol. 2005;29(12):1549–1557.
   PubMed Web of Science ®Google Scholar
• Shaheen SP, Talwalkar SS, Lin P, et al. Waldenström macroglobulinemia: a review of the entity and its differential diagnosis. Adv Anat Pathol. 2012;19(1):11–27.
   PubMed Web of Science ®Google Scholar
• Vijay A, Gertz MA. Waldenström macroglobulinemia. Blood. 2007;109(12):5096–5103.
   PubMed Web of Science ®Google Scholar
• Kyrtsonis MC, Levidou G, Korkolopoulou P, et al. CD138 expression helps distinguishing Waldenström’s macroglobulinemia (WM) from splenic marginal zone lymphoma (SMZL). Clin Lymphoma Myeloma Leuk. 2011;11(1):99–102.
   PubMed Web of Science ®Google Scholar
• San Miguel JF, Vidriales MB, Ocio E, et al. Immunophenotypic analysis of Waldenstrom’s macroglobulinemia. Semin Oncol. 2003;30(2):187–195.
   PubMed Web of Science ®Google Scholar
• Tzenou TK, Pangalis GA, Levidou G, et al. Increased immunohistochemical CD138 expression in Waldenström’s macroglobulinemia (WM) in comparison with splenic marginal zone lymphoma (SMZL). Blood. 2009;114(22):5008–5008.
   Google Scholar
• Millar EK, Waldron S, Spencer A, et al. CD10 positive thyroid marginal zone non-Hodgkin lymphoma. J Clin Pathol. 1999;52(11):849–850.
   PubMed Web of Science ®Google Scholar
• Wang E, West D, Kulbacki E. An unusual nodal marginal zone lymphoma with bright CD10 expression: a potential diagnostic pitfall. Am J Hematol. 2010;85(7):546–548.
   PubMed Web of Science ®Google Scholar
• Ocio EM, Hernandez JM, Mateo G, et al. Immunophenotypic and cytogenetic comparison of Waldenstrom’s macroglobulinemia with splenic marginal zone lymphoma. Clin Lymphoma. 2005;5(4):241–245.
   PubMedGoogle Scholar
• Poulain S, Roumier C, Venet-Caillault A, et al. Genomic landscape of CXCR4 mutations in Waldenström macroglobulinemia. Clin Cancer Res. 2016;22(6):1480–1488.
   PubMed Web of Science ®Google Scholar
• Arlindo EM, Marcondes NA, Fernandes FB, et al. Quantitative flow cytometric evaluation of CD200, CD123, CD43 and CD52 as a tool for the differential diagnosis of mature B-cell neoplasms. Rev Bras Hematol Hemoter. 2017;39(3):252–258.
   PubMedGoogle Scholar